About the Journal

SKIN is a peer-reviewed, open access, online only journal dedicated to providing free access globally to disseminate dermatological knowledge. Authors retain copyright in their articles, licensing publication of their content through use of Creative Commons CCBY license. The journal does not charge fees, and is supported by the National Society for Cutaneous Medicine. 


Read More

Current Issue

Vol. 8 No. 2 (2024): March 2024 Issue

Published: 2024-03-18

ISSUE HIGHLIGHTS

Clinical Management Recommendations

Evaluating the Efficacy and Safety of Bimekizumab for Plaque Psoriasis and Psoriatic Arthritis: An Expert Consensus Panel Report

Danny Zakria, Lauren Miller, Thomas Chao, Kirk Gautier, Holly Glover, Kristine Kucera, Andrea Nguyen, Leigh Ann Pansch, Rachel Printy, Cynthia Trickett, Joleen Volz, Milaan Shah, Joshua Burshtein

Page 1348-1364

PDF KOL SUMMARY

In-Depth Reviews

Iron Deficiency Anemia Pruritus: A Review with Proposed Mechanisms of Action

Christopher Nguyen, Monica Li

Page 1365-1373

PDF

Human Leukocyte Antigen DQB1 and its Implication in Scleroderma Pathogenesis: A Systematic Review

Dylan Thibaut, Vincent Doan, Kersten Schroeder

Page 1374-1383

PDF

Pitfalls in Laser-Based Device Tattoo Removal: A Literature Review

Nattanicha Chaisrimaneepan

Page 1384-1395

PDF

Research Letters

Assessing Knowledge of Appropriate Sunscreen Guidelines and Skin Cancer Prevention Among New York Yankees Attendees

Milaan Shah, Joshua Burshtein, Danny Zakria, Darrell Rigel

Page 1396-1398

PDF

Burnout Among Dermatology Residents and Fellows: A Survey Study

Alyssa Abdelnour, Kurt Ashack, Rosie Balk , Rushan Theunis, Jeff Miller

Page 1399-1404

PDF

Brief Articles

Angiokeratoma Corporis Diffusum in the Absence of Known Metabolic Disease and Systemic Features

Sokhna Seck, Taylor A. Bullock, Shilpi Khetarpal

Page 1405-1407

PDF

More Than Meets the Eye: Localized Bullous Eruption After Transfusion

Hamza Malick, Kyle C. Lauck, Priyanka Jalandarha, Dario Kivelevitch

Page 1408-1412

PDF

Dupilumab-induced Acanthosis Nigricans

Marita Yaghi, Teresa Ju, Jamie Hu, Arvin Jadoo, Andrea Maderal

Page 1413-1417

PDF

Verrucous Cyst in a 7-year-old Girl

Ehiaghe Anaba, Mumini Wemimo Rasheed

Page 1418-1422

PDF

Nevus Lipomatosus Cutaneous Superficialis: A Case Report in Egypt

Ahmed Sorour, Caroline Kruithoff, Ahmed Gamal, Moustafa Hassan Elhelw, Ahmed Sayed Zakaria El Sayed, Amani S. Abdelrahman, Yehia K. El-Refaie

Page 1423-1426

PDF

A Case of Atypical Presentation of Morpheaform Verrucous Sarcoidosis

Akash Rau, Evien Albazi, Kurt Ashack

Page 1427-1430

PDF

Progression of Atypical Fibroxanthoma to Metastatic Pleomorphic Dermal Sarcoma in a Lung Transplant Recipient

Mesa Bouni B.S., Ricardo Guerra MD, Matthew Viveiros B.S., Grace P. Hobayan B.S., David R. Carr MD MPH, Kathryn Shahwan MD

Page 1431-1434

PDF

Treatment of Steroid-Resistant Beard-Restricted Alopecia Areata with Baricitinib

Melissa Peri Zundell, Dr. Alexandra K. Golant

Page 1435-1438

PDF KOL SUMMARY

Cutaneous Ulcerations as the Presenting Sign of Acute Aortic Occlusion

Odera Ekeh, Zoë I. Smith, Justin J. Green

Page 1439-1441

PDF

Drug-Induced Erythema Annulare Centrifugum after Dupilumab Therapy: A Case Report.

Simran Kalsi, Santana Vandyke, Julia Barker, Joseph Pierson

Page 1442-1445

PDF

Histopathological Granuloma Formation in a Subacute Cutaneous Lupus Erythematosus Patient

Nattanicha Chaisrimaneepan

Page 1446-1450

PDF

Galli Galli Disease: A Challenging Diagnosis in a Bahraini Female Patient

McKenzie Dirr MD, Aysha Almedfa MD, Fatema Khamdan MD

Page 1451-1455

PDF

The Association Between Internet Search Patterns and Scabies Incidence Across the United States

Kennedy Sparling, Pooja Dhupati

Page 1456-1460

PDF

Short Communications

Retiform Plaques: An Additional Diagnostic Consideration

Hannah Mumber, Jimmy Lam, Lynne Goldberg, Christina Lam

Page 1461-1463

PDF

A Case of Hand-Foot Skin Reaction-like Eruption Associated with Pembrolizumab

Jade Young, Anna Eversman, Dina Poplausky, Yamato Suemitsu, George Niedt, Matthew Galsky, Joseph Sparano, Nicholas Gulati

Page 1464-1467

PDF

Skeletal Muscle Regeneration – A Rare Malignancy Mimicker Encountered in Mohs Micrographic Surgery

Ursa Bezan Petric, OLY, Derek Beaulieu, MD, Travis Vandergriff, MD, Divya Srivastava, MD

Page 1468-1470

Coinciding Erythema Nodosum and Sweet Syndrome

Philip Cohen

Page 1471-1472

PDF

Leaping over Leprosy

Kripa Ahuja, Grace DeSena

Page 1473-1474

PDF

SKINmages: Clinical Images in Dermatology

Nevus Sebaceous: A Midline Verrucous Lesion on a Neonate

Hannah McCowan, Meagan Olivet, Ruthie McTighe, Vinayak Nahar, Thy Huynh

Page 1475-1477

PDF

Posters from 2024 WCH and WCM Conferences: Psoriasis

Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Individual Patient PASI and PASI-HD Responses: Pooled DERMIS-1 and DERMIS-2 Phase 3 Trials

James Del Rosso, H. Chih-ho Hong, Leon Kircik, Melinda Gooderham, Mark Lebwohl, Kim Papp, Linda Stein Gold, Adelaide Hebert, Melissa Seal, David Krupa, David Chu, Patrick Burnett, David Berk, Robert Higham

Page s355

PDF

Apremilast for the Treatment of Psoriasis in Special Areas in Pediatric Patients in the SPROUT Study

Loretta Fiorillo, Emily Becker, Anna Belloni-Fortina, Susana Armesto, Peter Maes, Apostolos Kontzias, Maria Paris, Wendy Zhang, Zuoshun Zhang, Lisa Arkin

Page s356

PDF

Effect of Spesolimab on Achieving Sustained Disease Remission in Patients with Generalized Pustular Psoriasis: Results from the Effisayil 2 Study

Kenneth Gordon, Mark Lebwohl, Jonathan Barker, Tsen-Fang Tsai, Joseph Merola, Curdin Conrad, Min Zhang, Na Hu, Patrick Hofmann, Christian Thoma, Kilian Eyerich

Page s357

PDF

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in the Phase 3 Clinical Trials in Psoriasis, POETYK PSO-1 and PSO-2: Time to Meaningful Improvements in Itch as Assessed by the Psoriasis Symptoms and Signs Diary

Andrew F. Alexis, Joseph F. Merola, Yichen Zhong, Joe Zhuo, Brandon Becker, Andrew Napoli, Jessie Ross, Jennifer Beaumont, Michael DeRosa, Subhashis Banerjee, April W. Armstrong

Page s358

PDF

Expected Spesolimab Plasma Exposure following Intravenous and Subcutaneous Dosing in Patients with Generalized Pustular Psoriasis

Jason Hawkes, Jason Guercio, Sree Kurup, Xiujiang Li, Mark Lebwohl

Page s359

PDF

Spesolimab Use for Generalized Pustular Psoriasis Flare Prevention in Patients with Concomitant Plaque Psoriasis: Results from the Effisayil 2 Trial

Joseph Merola, Milan Anadkat, Neal Bhatia, Tina Bhutani, Laura Ferris, Arash Mostaghimi, .Jason Guercio, Christian Thoma, Ming Tang, Mark Lebwohl

Page s360

PDF

Measuring GPPGA, Pain, Symptom, and Quality of Life Index Scores in Untreated Generalized Pustular Psoriasis: Results from the Placebo Group of the Effisayil-2 Trial

Bruce Strober, Arash Mostaghimi, Milan Anadkat, Christian Thoma, Ming Tang, Jason Guercio, Mark Lebwohl

Page s361

PDF

Tapinarof Cream 1% Once Daily is Efficacious in the Treatment of Mild to Severe Plaque Psoriasis in the Head and Neck Region

Linda Stein Gold, George Michael Lewitt, Benjamin Lockshin, Philip M. Brown, Katherine Tillman, Nancy Fitzgerald, Brandon Kirsch, Anna M. Tallman, Abel D. Jarell
PDF

Tapinarof Cream 1% Once Daily Improves Patient-Reported Outcomes in the Treatment of Mild to Severe Plaque Psoriasis in the Head and Neck Region

George Michael Lewitt, Linda Stein Gold, Benjamin Lockshin, Philip M. Brown, Katherine Tillman, Nancy Fitzgerald, Brandon Kirsch, Anna M. Tallman, Abel Jarell
PDF

Deucravacitinib in Moderate Plaque Psoriasis: Efficacy in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Andrew Blauvelt, Neil J. Korman, Joseph F. Merola, Melinda Gooderham, Eugene Balagula, Rebecca Vanlandingham, Michelle Treitel, Keith Wittstock, Kim Hoyt, Subhashis Banerjee, Seemal R. Desai

Page s364

PDF

Deucravacitinib Long-Term Efficacy in Week 16 Placebo Crossovers: 3-year Results from the POETYK PSO Program

Mark Lebwohl, Richard B. Warren, Shinichi Imafuku, Jerry Bagel, April W. Armstrong, Thierry Passeron, Subhashis Banerjee, Renata M. Kisa, Eleni Vritzali, Matthew J. Colombo, Thomas Scharnitz, Kim Hoyt, Diamant Thaçi, Andrew Blauvelt

Page s365

PDF

Deucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials

April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim A. Papp, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt

Page s366

PDF

Gene Expression Differences Identified in Skin Samples of Mycosis Fungoides, Atopic Dermatitis, and Psoriasis

Aaron Farberg, Matthew Goldberg, Ann Quick, Christine Bailey, Olga Zolochevska, Jeff Wilkinson, Jonathan Silverberg, Peter Lio, John Koo, Jeffrey Weinberg, Mark Lebwohl

Page s367

PDF

Clinical Characteristics of Generalized Pustular Psoriasis Flares in the Real-World Setting

Layla Lavasani, Lawrence Rasouliyan, Megan Noe, Jamie Rhoads

Page s368

PDF

Bimekizumab Efficacy through Year 1 in Patients with Moderate to Severe Plaque Psoriasis Who Had Not Achieved a PASI 90 Response by Week 16: A Pooled Analysis from Four Phase 3/3B Trials

George Han, Alice B. Gottlieb, April Armstrong, Bruce Strober, Jennifer Soung, Heather Herr, Leah Davis, Mark Lebwohl

Page s369

PDF

Real-World Efficacy of Spesolimab: Reports from Four Patients with Generalized Pustular Psoriasis

Joe Tung, Jacquelyn Dorsal, Laura Rezac, Thomas Selby

Page s370

PDF

Effect of High-Dose Subcutaneous Spesolimab on Skin Manifestations: Results from the Pivotal Effisayil 2 Trial of Flare Prevention in Generalized Pustular Psoriasis

Bruce Strober, Matthias Augustin, Yayoi Tada, Amit Garg, Denis Jullien, Alice Gottlieb, Johann Gudjonsson, Na Hu, Patrick Hofmann, Christian Thoma, Angelo Marzano

Page s371

PDF

Atopic Dermatitis

Roflumilast Cream 0.15% in Patients with Atopic Dermatitis: Individual Patient Response from the Pooled INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Trials

Eric Simpson, Lawrence Eichenfield, James Del Rosso, Melinda Gooderham, H. Chih-ho Hong, Leon Kircik, Kim Papp, Adelaide Hebert, David Krupa, David Chu, Patrick Burnett, David Berk, Robert Higham

Page s372

PDF

Association Between Early Clinical Responses and Long-Term Outcomes With Ruxolitinib Cream Treatment in Mild to Moderate Atopic Dermatitis

Vimal H. Prajapati, Bob Geng, Andrew Blauvelt, Lawrence F. Eichenfield, Parbeer Grewal, Leon Kircik, Peter Lio, Charles Lynde, Eric L. Simpson, Haobo Ren, Daniel Sturm, Grace Wong, Chih-ho Hong

Page s373

PDF

A Checklist to Aid in Identifying Patients with Atopic Dermatitis Who are Candidates for Systemic Therapy

Jonathan Silverberg, Matthias Augustin, Lawrence Eichenfield, Peter Lio, Emma Guttman-Yassky, Amber Reck Atwater, Evangeline Pierce, Maria Jose Rueda, Alvin Li, Yolanda Munoz Maldonado, Eric Simpson

Page s374

PDF

Safety of Tralokinumab for the Treatment of Atopic Dermatitis in Patients with Up to 4.5 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials

Kristian Reich, Richard G. Langley, Juan Francisco Silvestre, Delphine Staumont-Salle, Antonio Costanzo, Andrew Pink, Amy Paller, Norito Katoh, Andreas Wollenberg, Richard B. Warren, Christian Bjerregård Øland, Ann-Marie Tindberg, Le Gjerum, Eric Simpson

Page s375

PDF

Continuous Tralokinumab Treatment over 4 Years in Adults with Moderate-to-Severe Atopic Dermatitis Provides Long-Term Disease Control

Andrew Blauvelt, Richard G. Langley, Ketty Peris, Juan Francisco Silvestre, Norito Katoh, Marie Tauber, Andreas Pinter, Mahreen Ameen, Melinda Gooderham, Christian Bjerregård Øland, Ann-Marie Tindberg, Le Gjerum, Kristian Reich

Page s376

PDF

Progressive and Sustained Disease Control in Patients with Atopic Dermatitis (AD) Aged 12–17 Years Treated with Tralokinumab for 52 Weeks

Andreas Wollenberg, Michael Cork, Chih-Ho Hong, Azra Kurbasic, Emilia Vacko, Amy Paller

Page s377

PDF

Factors Associated with Persistent Efficacy of Abrocitinib without Flare: A Multivariable Analysis of the JADE-REGIMEN Study

Jacob Thyssen, Jonathan Silverberg, Andrew Blauvelt, Paolo Criado, Walter Gubelin, Juan Ruano Ruiz, Ricardo Rojo, Ketti Terry, Hernan Valdez, Pinaki Biswas, Claire Feeney

Page s378

PDF

Integrated Safety Analysis of Abrocitinib in 635 Adolescent Patients With Moderate-To-Severe Atopic Dermatitis With Over 1000 Patient-Years of Exposure

Amy Paller, Lawrence Eichenfield, Jonathan Silverberg, Michael Cork, Christine Bangert, Alan Irvine, Stephan Weidinger, Sebastien Barbarot, Haiyun Fan, Justine Alderfer, Herwig Koppensteiner, Kanti Chittuluru

Page s379

PDF

Efficacy of Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis With Severe Itch at Baseline and in Subgroups by Baseline Thresholds of Severe Itch: A Post Hoc Analysis of the JADE COMPARE and JADE DARE Clinical Trials

H. Chi-Ho Hong, Melinda Gooderham, Shawn Kwatra, Stamatios Gregoriou, Gil Yosipovitch, Pinaki Biswas, Andrew Selfridge, Christopher Koulias, Erman Güler

Page s380

PDF

Efficacy Outcomes in Clinical Trials of Atopic Dermatitis Treatments: A Systematic Literature Review

Raj Chovatiya, Aseel Bin Sawad, Janine Fournier, Donna Fountain, Caroline Shaw, Jasmine Toomey, Mariola Vazquez, Anna M. Tallman, Doral Fredericks

Page s381

PDF

Psoriatic Arthritis

Early Oligoarticular Psoriatic Arthritis Responds to Treatment With Apremilast: Week 16 Results From FOREMOST - a Phase 4 Randomized Controlled Trial

Laure Gossec, Dafna Gladman, Laura Coates, Jacob Aelion, Jitendra Vasandani, Jyotsna Reddy, Rebecca Wang, Michele Brunori, Stephen Colgan, Philip Mease

Page s382

PDF

Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active Psoriatic Arthritis: Results from a Phase 2 Trial

Alice B. Gottlieb, April W. Armstrong, Joseph F. Merola, Andrew Napoli, Miroslawa Nowak, Subhashis Banerjee, Thomas Lehman, Philip J. Mease

Page s383

PDF

Skin Cancer

Non-invasive Gene Expression Analysis Rules Out Melanoma with High Negative Predictive Value Regardless of Skin Phototype

Maral Skelsey, Brent Loftis, Mark Kaufmann, Daniel Siegel, Neal Bhatia, Michael Walker, Andrew Rigby, John Whitaker, Steven Stone, Mary Mocia, Kaleigh O'Brien, Loren E. Clark, Burkhard Jansen

Page s384

PDF

The 40-gene Expression Profile (40-GEP) Test Identifies Cutaneous Squamous Cell Carcinoma (cSCC) Patients at High Risk of Metastasis within Lower-Staged Tumors to Better Guide Treatment Decisions

Ally-Khan Somani, Sherrif Ibrahim, Alison Fitzgerald, Jennifer Siegel, Anesh Prasai, Matthew Goldberg, Aaron Farberg, Javier Cañueto, Sarah Arron

Page s385

PDF

Real-World Evidence Confirms Risk Stratification of the 31-GEP and i31-GEP in Prospectively Tested Patients with Stage I-III Cutaneous Melanoma 

David Pariser, Jeffrey Sussman, Brian Martin, Lindsay Ackerman, Craig Kraffert, Abel Jarell

Page s386

PDF

Diagnostic Discordance Among Histopathological Reviewers for Difficult-to-Diagnose Melanocytic Lesions

Gregory Hosler, Matthew Goldberg, Sarah Estrada, Brendan O'Neil, Sapna Amin, Jose Plaza

Page s387

PDF

Efficacy Following Discontinuation of Sonidegib Treatment in Patients With Locally Advanced Basal Cell Carcinoma: Results From the BOLT 42-Month Analysis

Michael Migden, Meenal Kheterpal, Brent Moody, Kunal Patel, Leonard Lionnet, Sakthivel Sivam, Joe Conti, Nicholas Squittieri, Aaron Farberg

Page s388

PDF

Acne & Rosacea

Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne: Clinical Efficacy and Application Characteristics

Zoe Draelos, Linda Stein Gold, Leon Kircik, Emil Tanghetti

Page s389

PDF

Efficacy and Safety of Fixed-Dose Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne Vulgaris in Children and Adolescents

Lawrence Eichenfield, Adelaide Hebert, Julie Harper, Hilary Baldwin, Neal Bhatia, Linda Stein Gold, Leon Kircik, Emmy Graber, Emil Tanghetti, Andrew Alexis, James Del Rosso

Page s390

PDF

Maintenance Acne Treatment With Topical Tazarotene after Oral Isotretinoin: Overview and Case Reports

Shanna Miranti

Page s391

PDF

Efficacy and Safety of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Females with Moderate to Severe Acne: Post Hoc Analysis by Age

Julie Harper, Linda Stein Gold, Hilary Baldwin, Valerie Callender, Michael Gold, Heather Woolery-Lloyd, Leon Kircik

Page s392

PDF

Early Acne Improvements With Fixed-Dose Clindamycin Phosphate 1.2%/ Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel: What to Expect in the First 4 Weeks of Treatment

Julie Harper, Leon Kircik, Michael Gold, Adelaide Hebert, Jeffrey Sugarman, Lawrence Green, Linda Stein Gold, Hilary Baldwin, James Del Rosso, Eric Guenin

Page s393

PDF

Alopecia

Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata

Melissa Piliang, Jennifer Soung, Brett King, Jerry Shapiro, Lidia Rudnicka, Paul Farrant, Nina Magnolo, Bianca Piraccini, Xin Luo, Deborah Woodworth, Gregor Schaefer, Alexandre Lejeune, Robert Wolk

Page s394

PDF

Real-World Assessment of Disease Characteristics and Clinical Outcomes in Alopecia Areata in a Global Noninterventional Observational Cohort (ADAAGIO)

Keith Davis, Andrew Messenger, Sergio Vañó Galván, Helen Tran, Lynne Napatalung, Kent Hanson, Ernest Law

Page s395

PDF

Hidradenitis Suppurativa

Bimekizumab Response Maintenance to 48 Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II

John R. Ingram, Martina Porter, Raj Chovatiya, Evangelos J. Giamarellos-Bourboulis, Falk G. Bechara, Hideki Fujita, Wayne Gulliver, Edward Muller, Muhammad Bari, Robert Rolleri, Rob Byerly, Joslyn S Kirby

Page s396

PDF

Seborrheic Dermatitis

Clinical Efficacy and Patient Reported Impacts of Roflumilast Foam 0.3% in Seborrheic Dermatitis: An Analysis of STRATUM Data for Patients Unresponsive or Intolerant to Topical Corticosteroids

David Chu, Brett Stephenson, Jeff Lee, Breyanne Bannister, Conor Hickey, Tracy Westley, Matthew Zirwas

Page s397

PDF

Cosmetic

A New Peptide Skin-Brightening Facial Cream Demonstrated Clinical Improvement in Jawline Sagging, Discoloration and Overall Photodamage

Brenda Edison, BA, Li Feng, PhD, Surabhi Singh, MS, Ritamarie Guerrero, MS, Ramine Parsa, PhD, Ruchi Patel, MS , Marisa Dufort, MS, Barbara Green, MS/RPh

Page s398

PDF

Miscellaneous

Transungual Penetration and Antifungal Activity of Seven Prescription and Over-the-Counter Topical Antifungals: In Vitro Comparison

Ali Elabbasi, Ahmed Eltokhy, Warren Joseph, Boni Elewski, Mahmoud Ghannoum

Page s399

PDF

Concealing Meets Healing in the Treatment of Toenail Onychomycosis: A Review of Concurrent Nail Polish Use With Topical Efinaconazole 10% Solution

Bela Pandit, Boni Elewski, Tracey Vlahovic

Page s400

PDF

VP-102 Tolerability Evaluated by Concomitant Analgesic Medication Usage in Two Phase 3 Trials for Molluscum Contagiosum

Elaine Siegfried, Lawrence Eichenfield, Pearl Kwong, Jeffrey Sugarman, Susan Cutler, Gary Goldenberg

Page s401

PDF

Roflumilast Cream 0.3% for the Treatment of Recalcitrant Lichen Nitidus

Fabrizio Galimberti, Yumeng Li

Page s402

PDF

Bimekizumab Versus Secukinumab Continuous Maintenance of PASI 90 and PASI 100 Responses through One Year in Patients with Moderate to Severe Plaque Psoriasis: Post-HOC Results from the BE RADIANT Phase 3b Trial

Dr J.F. Merola, Prof. C. Conrad, Dr P. Foley, Prof. L. Iversen, Dr R.G. Langley, Dr G. Kokolakis, Leah Davis, Bengt Hoepken, Joe Dixon, Prof. R.B. Warren

Page s403

PDF
View All Issues